Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited in Vivo?

Investigative Radiology

Volumn 51, Issue 4, 2016, Pages 236-240

  Huckle, James E ^a   Altun, Ersan ^a   Jay, Michael ^b   Semelka, Richard C ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

contrast agent; gadolinium; GBCA; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID; CONTRAST MEDIUM;

BASAL GANGLION; DRUG RETENTION; END STAGE RENAL DISEASE; HEAVY METAL POISONING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY FUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SEVERE RENAL IMPAIRMENT; ANIMAL; BRAIN; CEREBELLUM NUCLEUS; GLOBUS PALLIDUS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM;

ANIMALS; BASAL GANGLIA; BRAIN; CEREBELLAR NUCLEI; CONTRAST MEDIA; GADOLINIUM; GLOBUS PALLIDUS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING;

EID: 84947776279     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000228     Document Type: Review

References (56)

1. Fakhran S, Alhilali L, Kale H, Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years. AJR Am J Roentgenol. 2015; 204: 703-706.
2. Matsumura T, Hayakawa M, Shimada F, Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci. 2013; 12: 297-304.
3. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104-1108.
4. FDA. FDA ALERT: Development of Serious and Sometimes Fatal Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy. [updated August 26, 2013]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142911.htm2006. Accessed August 3, 2015.
5. Bennett CL, Qureshi ZP, Sartor AO, Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012; 5: 82-88.
6. Nandwana SB, Moreno CC, Osipow MT, Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology. 2015; 276: 741-747.
7. Kanda T, Ishii K, Kawaguchi H, High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014; 270: 834-841.
8. Errante Y, Cirimele V, Mallio CA, Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014; 49: 685-690.
9. Kanda T, Fukusato T, Matsuda M, Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015; 276: 228-232.
10. Radbruch A, Weberling LD, Kieslich PJ, Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015; 275: 783-791.
11. Ramalho J, Castillo M, AlObaidy M, High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015; 276: 836-844.
12. Kanda T, Osawa M, Oba H, High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015; 275: 803-809.
13. McDonald RJ, McDonald JS, Kallmes DF, Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015; 275: 772-782.
14. Weberling LD, Kieslich PJ, Kickingereder P, Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015; 50: 743-748.
15. Lauffer RB,. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987; 87: 901-927.
16. Tweedle MF, Hagan JJ, Kumar K, Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991; 9: 409-415.
17. Tweedle MF, Gaughan GT, Hagan J, Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Int J Rad Appl Instrum B. 1988; 15: 31-36.
18. Weinmann HJ, Brasch RC, Press WR, Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol. 1984; 142: 619-624.
19. Tweedle MF, Wedeking P, Kumar K,. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995; 30: 372-380.
20. Broome DR, Girguis MS, Baron PW, Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007; 188: 586-592.
21. Biagi BA, Enyeart JJ,. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. Am J Physiol. 1990; 259: C515-C520.
22. Caldwell RA, Clemo HF, Baumgarten CM,. Using gadolinium to identify stretch-activated channels: technical considerations. Am J Physiol. 1998; 275: C619-C621.
23. Yang XC, Sachs F,. Block of stretch-activated ion channels in Xenopus oocytes by gadolinium and calcium ions. Science. 1989; 243: 1068-1071.
24. Bousquet JC, Saini S, Stark DD, Gd-DOTA: characterization of a new paramagnetic complex. Radiology. 1988; 166: 693-698.
25. Hao D, Ai T, Goerner F, MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012; 36: 1060-1071.
26. Meyer D, Schaefer M, Bonnemain B,. Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge. Invest Radiol. 1988; 23 (suppl 1): S232-S235.
27. Tweedle MF, Eaton SM, Eckelman WC, Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol. 1988; 23 (suppl 1): S236-S239.
28. Frenzel T, Lengsfeld P, Schirmer H, Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008; 43: 817-828.
29. Idée JM, Port M, Robic C, Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009; 30: 1249-1258.
30. Runge VM, Bradley WG, Brant-Zawadzki MN, Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology. 1991; 181: 701-709.
31. Harpur ES, Worah D, Hals PA, Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993; 28 (suppl 1): S28-S43.
32. 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. Int J Rad Appl Instrum B. 1988; 15: 395-402.
33. ICRP. Limits for Intakes of Radionuclides by Workers. ICRP Publication 30 (Part 1). Ann ICRP. 1979; 2: 67-68.
34. Zalikin GA, Moskalev IUI, Liubimova-Gerasimova RM, Distribution and biological activity of californium-252 [in Russian]. Radiobiologiia. 1972; 12: 894-897.
35. Sieber MA, Pietsch H, Walter J, A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008; 43: 65-75.
36. Sieber MA, Lengsfeld P, Frenzel T, Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008; 18: 2164-2173.
37. Pietsch H, Lengsfeld P, Jost G, Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009; 19: 1417-1424.
38. Pietsch H, Lengsfeld P, Steger-Hartmann T, Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009; 44: 226-233.
39. Kasokat T, Urich K,. Quantification of dechelation of gadopentetate dimeglumine in rats. Arzneimittelforschung. 1992; 42: 869-876.
40. Durbin PW,. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, eds. The Chemistry of the Actinide and Transactinide Elements. The Netherlands: Springer; 2006: 3339-3440.
41. 153Gd-BOPTA. Invest Radiol. 2005; 40: 705-714.
42. Spinazzi A, Ceriati S, Lorusso V, Safety and pharmacokinetics of BR21, a liver-specific CT agent, in healthy volunteers. Acad Radiol. 1998; 5 (suppl 1): S20-S22; discussion S28-S30.
43. Tien RD, Brasch RC, Jackson DE, Cerebral Erdheim-Chester disease: persistent enhancement with Gd-DTPA on MR images. Radiology. 1989; 172: 791-792.
44. Joffe P, Thomsen HS, Meusel M,. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998; 5: 491-502.
45. Cowper SE, Robin HS, Steinberg SM, Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000; 356: 1000-1001.
46. Marckmann P, Skov L, Rossen K, Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17: 2359-2362.
47. Abraham JL, Thakral C,. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 2008; 66: 200-207.
48. High WA, Ayers RA, Chandler J, Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007; 56: 21-26.
49. Kay J, Bazari H, Avery LL, Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008; 358: 827-838.
50. Schuhmann-Giampieri G, Krestin G,. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991; 26: 975-979.
51. Prince MR, Erel HE, Lent RW, Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003; 227: 639-646.
52. Gibby WA, Gibby KA, Gibby WA,. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol. 2004; 39: 138-142.
53. White GW, Gibby WA, Tweedle MF,. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006; 41: 272-278.
54. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics. 2009; 1: 479-488.
55. Birka M, Wentker KS, Lusmöller E, Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem. 2015; 87: 3321-3328.
56. Tweedle MF, Kanal E, Muller R,. Considerations in the selection of a new gadolinium-based contrast agent. Appl Radiol. 2014; (suppl May): 1-11.